Stock fact sheet · data as of
Bruker Corporation (BRKRP): fair value, margin of safety and Wheel Score
Healthcare · Medical - Devices · United States · Speculative / Distressed
Is BRKRP undervalued?
At 417.62 (close of 16 Oct 2026), BRKRP trades 1447% over the GLS average fair value of 27.00, with 0 of 3 models above the price. The stock earns none of the Wheel Score's Value points at this price. That is a statement about price against trailing fundamentals, not about the company's prospects - the Wall Street View and the Growth tab on the Quote page carry the forward numbers.
The average is built from just 3 models (DCF, 10 Cap, DDM) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.
The nightly engine files BRKRP under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for BRKRP
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 33.47 | -92% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | 44.59 | -89% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | 2.94 | -99% | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -73.72 | -118% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Bruker Corporation scores 5 of 9 on the Piotroski F-score: a middling result that falls one point short of the Sunday Scan's "6 or more" rule. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. A GLS Moat score of 3.7/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -0.2%, ROE -0.4%, ROA -0.1% - with debt at 0.83 times equity and a free-cash-flow yield of 1.1%.
The dividend yield is 0.35% with a payout ratio of -77% - a small yield that leaves most of the earnings in the business. Revenue comes mainly from Product 79%, Product and Service, Other 21% (quarter Q2 FY2026).
Institutional ownership scores 5/10, insider activity 3/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 5 / 9 | ROIC | -0.2% |
|---|---|---|---|
| GLS Moat | 3.7 / 10 | ROE | -0.4% |
| Debt / equity | 0.83 | ROA | -0.1% |
| Free-cash-flow yield | 1.1% | Payout ratio | -77% |
| Institutions | 5 / 10 | Insiders · Congress | 3 · 5 / 10 |
Wheel Score 28: No options
No options are listed on Bruker Corporation in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 28) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 1k shares a day on a market cap of $8.6B, with a beta of 1.39 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 11 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -1447% margin of safety | |
| Health | 11 / 20 | Piotroski 5/9 | |
| Moat | 6 / 15 | moat 3.7/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 11 / 20 | 1k shares/day, $8.6B cap, beta 1.39 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
Bruker Corporation reports earnings on 29 Oct 2026 (before the open) - inside the 14-day window the Sunday Scan avoids, because a put sold now would carry the report's gap risk.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Devices
The 12 companies below are the closest to Bruker Corporation by market cap within the Medical - Devices industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| BRKR Bruker Corporation | 56.54 | 18.80 | -201% | 45Weak | $8.6B |
| PODD Insulet Corp. | 133.93 | 153.23 | +13% | 88Prime | $9.3B |
| GKOS Glaukos Corporation | 165.60 | - | - | 45Weak | $9.8B |
| BIO Bio-Rad Laboratories, Inc. | 364.82 | 246.29 | -48% | 58Fair | $9.8B |
| GMED Globus Medical, Inc. | 78.84 | 112.94 | +30% | 92Prime | $10.6B |
| ALGN Align Technology, Inc. | 149.34 | 125.50 | -19% | 66Good | $10.6B |
| SNN Smith & Nephew plc | 27.88 | 37.94 | +27% | 90Prime | $11.7B |
| PEN Penumbra, Inc. | 320.12 | 139.38 | -130% | 54Fair | $12.6B |
| HAE Haemonetics Corporation | 121.29 | 65.74 | -84% | 60Fair | $5.5B |
| LIVN LivaNova PLC | 78.50 | 99.67 | +21% | 82Prime | $4.3B |
| ITGR Integer Holdings Corporation | 126.72 | 78.09 | -62% | 47Weak | $4.3B |
| ZBH Zimmer Biomet Holdings, Inc. | 91.77 | 134.51 | +32% | 87Prime | $17.5B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about BRKRP
Is BRKRP undervalued right now?
No: at 417.62 the stock trades 1447% above the GLS average fair value of 27.00 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of BRKRP and what does it mean?
BRKRP has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for BRKRP?
27.00 per share as of 16 Oct 2026 - the simple average of the 3 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Bruker Corporation report earnings next?
The next earnings report is due on 29 Oct 2026 (before the open), 13 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does BRKRP have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on BRKRP, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.